CORE--TRANSGENIC MOUSE/EMBRYONIC STEM CELL

描述：UCLA转基因小鼠/胚胎干细胞共享 资源是为了容纳个别调查员而设立的？S在 生产转基因和基因敲除小鼠，并为重新衍生 创造无特定病原体的小鼠的菌株。资源人员担任 许多不同调查的顾问提供关于具体情况的信息 转基因动物模型，DNA结构的设计和组装，以及 开发新的方法。也可以向调查人员提供材料 他们希望在自己的实验室里进行项目。有两个 资源的不同组成部分：转基因小鼠和ES细胞培养。 转基因小鼠设施成立于1991年。虽然不是由 NCI在上一次竞争续签申请中，该机构已 资助的设施？S手术，因为获得转基因和基因敲除 技术在癌症中心S的研究任务中扮演着至关重要的角色。这个 Facility进行DNA原核注射和囊胚注射 靶向ES细胞，重新衍生小鼠品系，并保持转基因动物 处于初始阶段的线条。 胚胎干细胞设施尚未投入使用。机构资金 已经被用来招聘一名导演，翻新空间，并提供 该设施的设备。一旦投入使用，这是一项正式的文化服务， 电穿孔、药物选择和ES克隆的扩展将是可用的。 使用情况的衡量标准是转基因设施的注射天数。 并针对ES设施的项目。的总容量 转基因设施是240天注射，胚胎干细胞设施是25个细胞 以项目为目标。加州大学洛杉矶分校的24名教职员工使用了这一资源 为66个单独项目提供援助。其中，由同行评审使用 癌症中心的成员总数为60%。业务预算总额 1997-1998年共享资源为259 672美元，请拨25%， 50%将从艾滋病收费中获得，25%来自 制度保障。

Description: The UCLA Transgenic Mouse/Embryonic Stem (ES) Cell Shared Resource was established to accommodate individual investigator?s needs in the production of transgenic and knockout mice and to provide for rederivation of strains to create specific pathogen-free mice. Resource personnel serve as consultants to many different investigations providing information on specific transgenic animal models, the design and assembly of DNA constructs, and the development of new methods. Materials can also be provided to investigators who wish to perform projects in their own laboratories. There are two separate components of the resource: Transgenic Mouse and ES Cell Culture. The Transgenic Mouse Facility was established in 1991. Although not funded by NCI in the last competitive renewal application, the institution has subsidized the facility?s operation because access to transgenic and knockout technology plays a vital role in the Cancer Center?s research mission. The facility performs pronuclear injections of DNA and blastocyst injections of targeted ES cells, rederives mouse strains, and maintains transgenic animal lines in their initial stages. The Embryonic Stem Cell Facility is not yet operational. Institutional funds have been utilized to recruit a director, renovate space, and provide equipment for the facility. Once operational, a formal service for culture, electroporation, drug selection, and expansion of ES clones will be available. The measure of usage is based on injection days for the transgenic facility and targeting projects for the ES facility. The total capacity for the transgenic facility is 240 injection days and for the ES facility, 25 cell targeting projects. Twenty four UCLA faculty members used the resource representing assistance to 66 individual projects. Of these, use by peerreviewed Cancer Center members totaled 60 percent. The total operating budget of the shared resource for 1997-1998 is $259,672, with 25 percent requested, 50 percent to be obtained from AIDS chargebacks, and 25 percent from institutional support.